Professor of Surgery
Department of Surgery, Shanghai Public Health Clincial Center
Dr. Yangbing Zhao is an Associate Professor and the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction via genetically engineered T cells. For the next two years, he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group at the Surgery Branch of the National Cancer Institute as a senior research fellow, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 and VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as the Director of TCEL. His research work led to multiple clinical trials to treat cancer patients using TCRT or CART against NY-ESO-1, CD19, Mesothelin, cMet, GD2 and CD123 at University of Pennsylvania, as well as first in human CRISPR/CAS9 application in the world.
Dr. Zhao was directly involved in the development and commercialization of both Yescarta and kymriah that are only two FDA approved CART products. He has over 30 years research experiences in transplantation and tumor immunology and 20 years T cell engineering, authored over 50 publications and over 90 patent applications. Dr. Zhao is the Co-founder of Tmunity Therapeutics Inc.